AG
PBYI icon

Advisor Group’s Puma Biotechnology PBYI Stock Holding History

Advisor Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$38K Buy
4,400
+349
+9% +$2.89K ﹤0.01% 3604
2019
Q3 		$43K Buy
4,051
+1,996
+97% +$21.6K ﹤0.01% 3504
2019
Q2 		$26K Buy
2,055
+501
+32% +$11.5K ﹤0.01% 3806
2019
Q1 		$60K Buy
1,554
+714
+85% +$21.8K ﹤0.01% 3261
2018
Q4 		$17K Sell
840
-380
-31% -$11.4K ﹤0.01% 3924
2018
Q3 		$56K Buy
1,220
+978
+404% +$47.2K ﹤0.01% 3200
2018
Q2 		$14K Sell
242
-6
-2% -$348 ﹤0.01% 3913
2018
Q1 		$17K Sell
248
-148
-37% -$11.1K ﹤0.01% 3782
2017
Q4 		$39K Buy
396
+75
+23% +$8.39K ﹤0.01% 3258
2017
Q3 		$38K Buy
321
+289
+903% +$26.9K ﹤0.01% 3138
2017
Q2 		$3K Hold
32
– – ﹤0.01% 4422
2017
Q1 		$1K Sell
32
-500
-94% -$18.2K ﹤0.01% 4556
2016
Q4 		$16K Buy
532
+489
+1,137% +$21.1K ﹤0.01% 3366
2016
Q3 		$2K Buy
43
+21
+95% +$1.06K ﹤0.01% 4180
2016
Q2 		$0 Buy
+22
New +$688 ﹤0.01% 4466

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Advisor Group's PBYI Position: Q4 2019 in Review

Advisor Group increased its Puma Biotechnology (PBYI) stake by 8.6% in Q4 2019, buying an estimated $2.89K and bringing the position to 4,400 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #3604.

Advisor Group first reported a position in PBYI in Q2 2016 and has held it in 15 quarters since. The position peaked at $60K in Q1 2019. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

  • Advisor Group held 4,400 shares of Puma Biotechnology worth $38K as of Q4 2019.
  • Advisor Group bought 349 Puma Biotechnology shares in Q4 2019, an estimated $2.89K.
  • Puma Biotechnology made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3604 holding.
  • Advisor Group first reported a position in Puma Biotechnology in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Puma Biotechnology position peaked at $60K in Q1 2019.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.